The company develops and commercializes new medicines, particularly T-cell activated cancer medicines, and provides services in the areas of research and development, clinical trials, pharmacology, toxicology and analytics.
AI-generated
Offering
Products & services
Industry:Research & Development
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Antibody-based T-cell engagers for oncology and autoimmune diseases, developed with the M-gager® platform for high tumor selectivity and targeted immune-cell control.
M-gager® platform
Proprietary antibody-fragment platform for developing selective T-cell engagers, with a modular binding architecture, good drug properties and scalable manufacturing.
Oncology programs
Tumor-selective T-cell engagers against solid tumors that are difficult to treat, including CDR404, CDR505, CDR609 and CDR813 for different cancer antigens.
Autoimmunity programs
Targeted therapeutics for autoimmune diseases that address specific immune-cell populations and aim to reset the immune system to a healthy state.
CDR404
Bivalent, bispecific M-gager® against MAGE-A4-positive solid tumors, currently in a Phase 1 study evaluating safety, tolerability and first efficacy.